Search

Your search keyword '"Montemagno, Christopher"' showing total 180 results
Start Over Author "Montemagno, Christopher"
180 results on '"Montemagno, Christopher"'

1. Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001

Author

Montemagno, Christopher, Jacquel, Arnaud, Pandiani, Charlotte, Rastoin, Olivia, Dawaliby, Rosie, Schmitt, Thomas, Bourgoin, Maxence, Palenzuela, Héliciane, Rossi, Anne-Laure, Ambrosetti, Damien, Durivault, Jerome, Luciano, Frederic, Borchiellini, Delphine, Le Du, Julie, Gonçalves, Leticia Christina Pires, Auberger, Patrick, Benhida, Rachid, Kinget, Lisa, Beuselinck, Benoit, Ronco, Cyril, Pagès, Gilles, and Dufies, Maeva

Published
2024
Full Text
View/download PDF

6. FIGURE 4 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance

Author

Echavidre, William, primary, Durivault, Jérôme, primary, Gotorbe, Célia, primary, Blanchard, Thays, primary, Pagnuzzi, Marina, primary, Vial, Valérie, primary, Raes, Florian, primary, Broisat, Alexis, primary, Villeneuve, Rémy, primary, Amblard, Régis, primary, Garnier, Nicolas, primary, Ortholan, Cécile, primary, Faraggi, Marc, primary, Serrano, Benjamin, primary, Picco, Vincent, primary, and Montemagno, Christopher, primary

Published
2023
Full Text
View/download PDF

7. Figure S1 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance

Author

Echavidre, William, primary, Durivault, Jérôme, primary, Gotorbe, Célia, primary, Blanchard, Thays, primary, Pagnuzzi, Marina, primary, Vial, Valérie, primary, Raes, Florian, primary, Broisat, Alexis, primary, Villeneuve, Rémy, primary, Amblard, Régis, primary, Garnier, Nicolas, primary, Ortholan, Cécile, primary, Faraggi, Marc, primary, Serrano, Benjamin, primary, Picco, Vincent, primary, and Montemagno, Christopher, primary

Published
2023
Full Text
View/download PDF

8. FIGURE 2 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance

Author

Echavidre, William, primary, Durivault, Jérôme, primary, Gotorbe, Célia, primary, Blanchard, Thays, primary, Pagnuzzi, Marina, primary, Vial, Valérie, primary, Raes, Florian, primary, Broisat, Alexis, primary, Villeneuve, Rémy, primary, Amblard, Régis, primary, Garnier, Nicolas, primary, Ortholan, Cécile, primary, Faraggi, Marc, primary, Serrano, Benjamin, primary, Picco, Vincent, primary, and Montemagno, Christopher, primary

Published
2023
Full Text
View/download PDF

9. FIGURE 6 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance

Author

Echavidre, William, primary, Durivault, Jérôme, primary, Gotorbe, Célia, primary, Blanchard, Thays, primary, Pagnuzzi, Marina, primary, Vial, Valérie, primary, Raes, Florian, primary, Broisat, Alexis, primary, Villeneuve, Rémy, primary, Amblard, Régis, primary, Garnier, Nicolas, primary, Ortholan, Cécile, primary, Faraggi, Marc, primary, Serrano, Benjamin, primary, Picco, Vincent, primary, and Montemagno, Christopher, primary

Published
2023
Full Text
View/download PDF

10. FIGURE 3 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance

Author

Echavidre, William, primary, Durivault, Jérôme, primary, Gotorbe, Célia, primary, Blanchard, Thays, primary, Pagnuzzi, Marina, primary, Vial, Valérie, primary, Raes, Florian, primary, Broisat, Alexis, primary, Villeneuve, Rémy, primary, Amblard, Régis, primary, Garnier, Nicolas, primary, Ortholan, Cécile, primary, Faraggi, Marc, primary, Serrano, Benjamin, primary, Picco, Vincent, primary, and Montemagno, Christopher, primary

Published
2023
Full Text
View/download PDF

11. FIGURE 5 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance

Author

Echavidre, William, primary, Durivault, Jérôme, primary, Gotorbe, Célia, primary, Blanchard, Thays, primary, Pagnuzzi, Marina, primary, Vial, Valérie, primary, Raes, Florian, primary, Broisat, Alexis, primary, Villeneuve, Rémy, primary, Amblard, Régis, primary, Garnier, Nicolas, primary, Ortholan, Cécile, primary, Faraggi, Marc, primary, Serrano, Benjamin, primary, Picco, Vincent, primary, and Montemagno, Christopher, primary

Published
2023
Full Text
View/download PDF

12. Table S1 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance

Author

Echavidre, William, primary, Durivault, Jérôme, primary, Gotorbe, Célia, primary, Blanchard, Thays, primary, Pagnuzzi, Marina, primary, Vial, Valérie, primary, Raes, Florian, primary, Broisat, Alexis, primary, Villeneuve, Rémy, primary, Amblard, Régis, primary, Garnier, Nicolas, primary, Ortholan, Cécile, primary, Faraggi, Marc, primary, Serrano, Benjamin, primary, Picco, Vincent, primary, and Montemagno, Christopher, primary

Published
2023
Full Text
View/download PDF

13. Data from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance

Author

Echavidre, William, primary, Durivault, Jérôme, primary, Gotorbe, Célia, primary, Blanchard, Thays, primary, Pagnuzzi, Marina, primary, Vial, Valérie, primary, Raes, Florian, primary, Broisat, Alexis, primary, Villeneuve, Rémy, primary, Amblard, Régis, primary, Garnier, Nicolas, primary, Ortholan, Cécile, primary, Faraggi, Marc, primary, Serrano, Benjamin, primary, Picco, Vincent, primary, and Montemagno, Christopher, primary

Published
2023
Full Text
View/download PDF

14. FIGURE 1 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance

Author

Echavidre, William, primary, Durivault, Jérôme, primary, Gotorbe, Célia, primary, Blanchard, Thays, primary, Pagnuzzi, Marina, primary, Vial, Valérie, primary, Raes, Florian, primary, Broisat, Alexis, primary, Villeneuve, Rémy, primary, Amblard, Régis, primary, Garnier, Nicolas, primary, Ortholan, Cécile, primary, Faraggi, Marc, primary, Serrano, Benjamin, primary, Picco, Vincent, primary, and Montemagno, Christopher, primary

Published
2023
Full Text
View/download PDF

15. Integrin-αvβ3 is a therapeutically targetable fundamental factor in medulloblastoma tumorigenicity and radioresistance

Author

Echavidre, William, primary, Durivault, Jerome, additional, Gotorbe, Célia, additional, Blanchard, Thays, additional, Pagnuzzi, Marina, additional, Vial, Valérie, additional, Raes, Florian, additional, Broisat, Alexis, additional, Villeneuve, Rémy, additional, Amblard, Régis, additional, Garnier, Nicolas, additional, Ortholan, Cécile, additional, Faraggi, Marc, additional, Serrano, Benjamin, additional, Picco, Vincent, additional, and Montemagno, Christopher, additional

Published
2023
Full Text
View/download PDF

18. A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma

Author

Montemagno, Christopher, primary, Durivault, Jérôme, additional, Gastaldi, Cécile, additional, Dufies, Maeva, additional, Vial, Valérie, additional, He, Xingkang, additional, Ambrosetti, Damien, additional, Kamenskaya, Anna, additional, Negrier, Sylvie, additional, Bernhard, Jean‐Christophe, additional, Borchiellini, Delphine, additional, Cao, Yihai, additional, and Pagès, Gilles, additional

Published
2023
Full Text
View/download PDF

19. Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?

Author

de Leiris, Nicolas, Leenhardt, Julien, Boussat, Bastien, Montemagno, Christopher, Seiller, Alexandre, Phan Sy, Olivier, Roux, Julie, Laramas, Mathieu, Verry, Camille, Iriart, Carole, Fiard, Gaelle, Long, Jean-Alexandre, Descotes, Jean-Luc, Vuillez, Jean-Philippe, Riou, Laurent, and Djaileb, Loïc

Published
2020
Full Text
View/download PDF

21. Suppl. Movie 2 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

22. Supp. Figure 3 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

23. Supp. Figure 4 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

24. Prunier et al. Supplementary information from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

25. Supp. Figure 2 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

26. Suppl. Movie 3 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

27. Supp. Figure 1 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

28. Supp. Figure 5 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

29. Supp. Figure 7 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

30. Data from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

31. Suppl. Movie 1 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

32. Supp. Figure 6 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

33. Integrin-alpha V beta 3 is a fundamental factor in medulloblastoma tumorigenicity and radioresistance: A new game for an old player

Author

Echavidre, William, primary, Durivault, Jerome, additional, Gotorbe, Celia, additional, Blanchard, Thays, additional, Pagnuzzi, Marina, additional, Vial, Valerie, additional, Raes, Florian, additional, Broisat, Alexis, additional, Villeneuve, Remy, additional, Amblard, Regis, additional, Garnier, Nicolas, additional, Ortholan, Cecile, additional, Faraggi, Marc, additional, Serrano, Benjamin, additional, Picco, Vincent, additional, and Montemagno, Christopher, additional

Published
2023
Full Text
View/download PDF

34. Quantitative analysis of 99mTc-pertechnetate thyroid uptake with a large-field CZT gamma camera: feasibility and comparison between SPECT/CT and planar acquisitions.

Author

Serrano, Benjamin, Amblard, Régis, Beaumont, Tiffany, Hugonnet, Florent, Dietz, Matthieu, Berthier, Frédéric, Garnier, Nicolas, Villeneuve, Rémy, Nataf, Valérie, Mocquot, François, Montemagno, Christopher, Faraggi, Marc, and Paulmier, Benoît

Subjects
SINGLE-photon emission computed tomography, SCINTILLATION cameras, CADMIUM zinc telluride, THYROID gland, COMPUTED tomography
Abstract

Purpose: The main objective of this study was to evaluate the ability of a large field Cadmium Zinc Telluride (CZT) camera to estimate thyroid uptake (TU) on single photon emission computed tomography (SPECT) images with and without attenuation correction (Tomo-AC and Tomo-NoAC) compared with Planar acquisition in a series of 23 consecutive patients. The secondary objective was to determine radiation doses for the tracer administration and for the additional Computed Tomography (CT) scan. Methods: Cross-calibration factors were determined using a thyroid phantom, for Planar, Tomo-AC and Tomo-NoAC images. Then Planar and SPECT/CT acquisitions centered on the thyroid were performed on 5 anthropomorphic phantoms with activity ranging from 0.4 to 10 MBq, and 23 patients after administration of 79.2 ± 3.7 MBq of [99mTc]-pertechnetate. We estimated the absolute thyroid activity (AThA) for the anthropomorphic phantoms and the TU for the patients. Radiation dose was also determined using International Commission on Radiological Protection (ICRP) reports and VirtualDoseTMCT software. Results: Cross-calibration factors were 66.2 ± 4.9, 60.7 ± 0.7 and 26.5 ± 0.3 counts/(MBq s), respectively, for Planar, Tomo-AC and Tomo-NoAC images. Theoretical and estimated AThA for Planar, Tomo-AC and Tomo-NoAC images were statistically highly correlated (r < 0.99; P < 10–4) and the average of the relative percentage difference between theoretical and estimated AThA were (8.6 ± 17.8), (− 1.3 ± 5.2) and (12.8 ± 5.7) %, respectively. Comparisons between TU based on different pairs of images (Planar vs Tomo-AC, Planar vs Tomo-NoAC and Tomo-AC vs Tomo-NoAC) showed statistically significant correlation (r = 0.972, 0.961 and 0.935, respectively; P < 10–3). Effective and thyroid absorbed doses were, respectively (0.34CT + 0.95NM) mSv, and (3.88CT + 1.74NM) mGy. Conclusion: AThA estimation using Planar and SPECT/CT acquisitions on a new generation of CZT large-field cameras is feasible. In addition, TU on SPECT/CT was as accurate as conventional planar acquisition, but the CT induced additional thyroid exposure. Trial registration Name of the registry: Thyroid Uptake Quantification on a New Generation of Gamma Camera (QUANTHYC). Trial number: NCT05049551. Registered September 20, 2021—Retrospectively registered, https://clinicaltrials.gov/ct2/show/record/NCT05049551?cntry=MC&draw=2&rank=4. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. New splice variants of VEGF as relevant targets for the treatment of renal cell carcinoma

Author

Montemagno, Christopher, primary, Durivault, Jérôme, additional, Gastaldi, Cécile, additional, Dufies, Maeva, additional, Vial, Valérie, additional, He, Xingkang, additional, Ambrosetti, Damien, additional, Kamenskaya, Anna, additional, Négrier, Sylvie, additional, Bernhard, Jean Christophe, additional, Borchiellini, Delphine, additional, Cao, Yihai, additional, and Pagès, Gilles, additional

Published
2022
Full Text
View/download PDF

37. Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma

Author

Pagnuzzi-Boncompagni, Marina, primary, Picco, Vincent, additional, Vial, Valérie, additional, Planas-Bielsa, Victor, additional, Vandenberghe, Ashaina, additional, Daubon, Thomas, additional, Derieppe, Marie-Alix, additional, Montemagno, Christopher, additional, Durivault, Jérôme, additional, Grépin, Renaud, additional, Martial, Sonia, additional, Doyen, Jérôme, additional, Gavard, Julie, additional, and Pagès, Gilles, additional

Published
2021
Full Text
View/download PDF

38. In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study

Author

Montemagno, Christopher, primary, Serrano, Benjamin, additional, Durivault, Jérôme, additional, Nataf, Valérie, additional, Mocquot, François, additional, Amblard, Régis, additional, Vial, Valérie, additional, Ronco, Cyril, additional, Benhida, Rachid, additional, Dufies, Maeva, additional, Faraggi, Marc, additional, and Pagès, Gilles, additional

Published
2021
Full Text
View/download PDF

39. Cancer‐associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti‐angiogenic therapy

Author

Ambrosetti, Damien, primary, Coutts, Michael, additional, Paoli, Charlotte, additional, Durand, Matthieu, additional, Borchiellini, Delphine, additional, Montemagno, Christopher, additional, Rastoin, Olivia, additional, Borderie, Arnaud, additional, Grepin, Renaud, additional, Rioux‐Leclercq, Nathalie, additional, Bernhard, Jean‐Christophe, additional, Pagès, Gilles, additional, and Dufies, Maeva, additional

Published
2021
Full Text
View/download PDF

40. Additional file 6 of Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma

Author

Dumond, Aurore, Brachet, Etienne, Durivault, Jérôme, Vial, Valérie, Puszko, Anna K., Lepelletier, Yves, Montemagno, Christopher, Pagnuzzi-Boncompagni, Marina, Hermine, Olivier, Garbay, Christiane, Lagarde, Nathalie, Montes, Matthieu, Demange, Luc, Grépin, Renaud, and Pagès, Gilles

Abstract

Additional file 6: Fig. S5. In-vivo effects of NRPa-308 on mice weight. The weight of nude mice xenografted with 786-O cells and treated with increasing doses of NRPa-308 was evaluated once a week.

Published
2021
Full Text
View/download PDF

41. Additional file 1 of Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma

Author

Dumond, Aurore, Brachet, Etienne, Durivault, Jérôme, Vial, Valérie, Puszko, Anna K., Lepelletier, Yves, Montemagno, Christopher, Pagnuzzi-Boncompagni, Marina, Hermine, Olivier, Garbay, Christiane, Lagarde, Nathalie, Montes, Matthieu, Demange, Luc, Grépin, Renaud, and Pagès, Gilles

Abstract

Additional file 1: Table S1. List of oligonucleotides used in qPCR experiments. Table S2. Recapitulative table of the expression of NRP1 and NRP2 in KO and knock-down cells. Table S3. Recapitulative table of the expression of VEGFA and VEGFC in KO and knock-down cells. Table S4. NRP1 and NRP2 binding site descriptors computed with DogSite Scorer (Nb: number, HBA: Hydrogen Bond Acceptor, HBD: Hydrogen Bond Donor, AA: amino acids).

Published
2021
Full Text
View/download PDF

42. Additional file 2 of Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma

Author

Dumond, Aurore, Brachet, Etienne, Durivault, Jérôme, Vial, Valérie, Puszko, Anna K., Lepelletier, Yves, Montemagno, Christopher, Pagnuzzi-Boncompagni, Marina, Hermine, Olivier, Garbay, Christiane, Lagarde, Nathalie, Montes, Matthieu, Demange, Luc, Grépin, Renaud, and Pagès, Gilles

Abstract

Additional file 2: Fig. S1. Study of down-regulation of NRPs by shRNA in 786-O cells. (A-B) Effects of the downregulation of NRP by shRNA on NRP1 and NRP2 mRNA expression measured by qPCR. (C) Effects on cell metabolic activity measured by MTT assays. (D) Down-regulation of NRPs decreased cell migration. Bevacizumab increased this effect for NRP1 down-regulation. (E) Down-regulation of NRPs had no effect on VEGFA and VEGFC production measured by ELISA. *p

Published
2021
Full Text
View/download PDF

43. Additional file 5 of Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma

Author

Dumond, Aurore, Brachet, Etienne, Durivault, Jérôme, Vial, Valérie, Puszko, Anna K., Lepelletier, Yves, Montemagno, Christopher, Pagnuzzi-Boncompagni, Marina, Hermine, Olivier, Garbay, Christiane, Lagarde, Nathalie, Montes, Matthieu, Demange, Luc, Grépin, Renaud, and Pagès, Gilles

Abstract

Additional file 5: Fig. S4. NRPs KO in RENCA tumor cells inhibited experimental RCC growth in immunodeficient mice. (A) Experimental tumors in nude mice were obtained after injection of 3 × 105 control (Ctrl, 10 mice) or NRPs KO RENCA cells (5 mice for each condition). One NRP1 KO clone (4.1 7) and one NRP2 KO clone (5.1 8) were injected. Tumor volume at the indicated times is presented. Each curve stands for an individual mouse.

Published
2021
Full Text
View/download PDF

44. Additional file 3 of Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma

Author

Dumond, Aurore, Brachet, Etienne, Durivault, Jérôme, Vial, Valérie, Puszko, Anna K., Lepelletier, Yves, Montemagno, Christopher, Pagnuzzi-Boncompagni, Marina, Hermine, Olivier, Garbay, Christiane, Lagarde, Nathalie, Montes, Matthieu, Demange, Luc, Grépin, Renaud, and Pagès, Gilles

Abstract

Additional file 3: Fig. S2. Effects of NRP1 or NRP2 gene invalidation in RENCA cells. (A) NRP1 and NRP2 protein levels were evaluated by flow cytometry in control (RENCA), in #NRP1 4.1.7 and #NRP2 5.1.8 clones. (B) Effects of NRPs KO on RENCA cell metabolic activity measured by MTT assays. (C) Effects of NRPs KO in RENCA cells on the VEGFA and VEGFC protein levels measured by ELISA. *p

Published
2021
Full Text
View/download PDF

47. In Vivo Biodistribution and Efficacy Evaluation of NeoB, a Radiotracer Targeted to GRPR, in Mice Bearing Gastrointestinal Stromal Tumor

Author

Montemagno, Christopher, primary, Raes, Florian, additional, Ahmadi, Mitra, additional, Bacot, Sandrine, additional, Debiossat, Marlène, additional, Leenhardt, Julien, additional, Boutonnat, Jean, additional, Orlandi, Francesca, additional, Barbato, Donato, additional, Tedesco, Mattia, additional, Ghezzi, Catherine, additional, Perret, Pascale, additional, and Broisat, Alexis, additional

Published
2021
Full Text
View/download PDF

48. Cabozantinib, a Promising Therapeutic Strategy for Resistant Head and Neck Squamous Cell Carcinoma Patients

Author

Hagege, Anais, primary, Rastoin, Olivia, additional, Ambrosetti, Damien, additional, Boyer, Julien, additional, He, Xingkang, additional, Rousset, Julie, additional, Montemagno, Christopher, additional, Parola, Julien, additional, Bourget, Isabelle, additional, Luciano, Frederic, additional, Saada-Bouzid, Esma, additional, Bozec, Alexandre, additional, Cao, Yihai, additional, Pagès, Gilles, additional, and Dufies, Maeva, additional

Published
2021
Full Text
View/download PDF

49. Tc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma

Author

Montemagno, Christopher, Cassim, Shamir, Trichanh, Dimitry, Savary, Clara, Pouysségur, Jacques, Pagès, Gilles, Fagret, Daniel, Broisat, Alexis, Ghezzi, Catherine, Centre Scientifique de Monaco (CSM), Radiopharmaceutiques biocliniques (LRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université Nice Sophia Antipolis (... - 2019) (UNS), and Jonchère, Laurent

Subjects
[SDV] Life Sciences [q-bio], noninvasive imaging, endocrine system diseases, Mesothelin, [SDV]Life Sciences [q-bio], PDAC, digestive system diseases
Abstract

International audience; Mesothelin is a membrane-associated protein overexpressed in pancreatic ductal adenocarcinoma (PDAC). Some mesothelin-targeted therapies are in clinical development but the identification of patients eligible for such therapies is still challenging. The objective of this study was to perform the imaging of mesothelin in mice models of PDAC with a technetium-labeled anti-mesothelin single-domain antibody (Tc-A1).

Published
2019

50. Neuropilin 1 and Neuropilin 2 Gene Invalidation or Pharmacological Inhibition Reveals Their Relevance for the Treatment of Metastatic Renal Cell Carcinoma

Author

Dumond, Aurore, primary, Brachet, Etienne, additional, Durivault, Jérôme, additional, Vial, Valérie, additional, Puszko, Anna, additional, Lepelletier, Yves, additional, Montemagno, Christopher, additional, Pagnuzzi-Boncompagni, Marina, additional, Hermine, Olivier, additional, Garbay, Christiane, additional, Lagarde, Nathalie, additional, Montes, Matthieu, additional, Demange, Luc, additional, Grépin, Renaud, additional, and Pagès, Gilles, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results